Improvement of the ocular bioavailability of carteolol by ion pair

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 5, 2006, Pages 333-339

  Higashiyama, Masayo ^a   Tajika, Tetsuya ^a   Inada, Katsuhiro ^a   Ohtori, Akira ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CARTEOLOL; CROTONIC ACID DERIVATIVE; FATTY ACID; HEXANOIC ACID; OCTANOL; SORBIC ACID; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; GLAUCOMA; ION TRANSPORT; LIPOPHILICITY; MALE; NONHUMAN; PARTITION COEFFICIENT; RABBIT;

ABSORPTION; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CARTEOLOL; DRUG DESIGN; EYE; FATTY ACIDS; MALE; RABBITS;

EID: 33750741470     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.333     Document Type: Article

References (26)

1. Ohtake, Y., Tanino, T., Kimura, I., et al. Long-term efficacy and safety of combines topical antiglaucoma therapy-timolol and unoprostone versus betaxolol and unoprostone. Nippon Ganka Gakkai Zasshi (J. Jpn. Ophthalmol. Soc.) 108:23-28, 2004.
2. DeSantis, Jr., L.M. β-adrenergic receptor-blocking agents. In: Mauger, T.F., Craig, E.L. (Eds.), Havener's Ocular Pharmacology, 6th ed. St Louis, MO: Mosby-Year Book, 1994:84-112.
3. Shields, M.B. Adrenergic inhibitors. In: Textbook of Glaucoma, 3rd ed. Baltimore, MD: Williams & Wilkins, 1992:480-499.
4. Uusitalo, H., Nino, J., Tahvanainen K., et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta. Ophthalmol. Scand. 83:723-728, 2005.
5. Tissie, G., Sebastian, C., Elena, P.P., et al. Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit. J. Ocul. Pharmacol. Ther. 18:65-73, 2002.
6. Rozier, A., Mazuel, C., Grove, J., et al. Gelrite: A novel, ion-activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm. 57:163-168, 1989.
7. Schenker, H.I., and Silver, L.H. Long-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution 0.5% in a 12-month study. Am. J. Ophthalmol. 130:145-150, 2000.
8. Wada, T., Nagoshi, K., Tahira, N., et al. WP-934: Developed reversible thermosetting, in situ gelling ophthalmic solution (I)-timolol concentrations in ocular tissues and plasma after single instillation in the eyes of albino rabbits. Atarashti Ganka (J. Eye) 16:1013-1018, 1999.
9. Wada, T., Toyoda, Y., Takeuchi, M., et al. Precorneal residence of a newly developed reversible thermosetting, in situ gelling ophthalmic vehicle of WP-934 (Rysmon TG). Atarashii Ganka (J. Eye) 16:1311-1314, 1999.
10. Shedden, A.H. Timolol maleate in gel-forming solution: A novel formulation of timolol maleate. Chibret Int. J. Ophthalmol. 10:32-36, 1994.
11. Physicians' Desk Reference for Ophthalmic Medications. 31st ed. 2003, Montvale, NJ: Thomson Medical Economics, 2003:261, 281.
12. Taniguchi, T., and Kitazawa, Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr. Opin. Ophthalmol. Pharm. 8:55-58, 1997.
13. Bartlett, J.D., Olivier, M., Richardson, T., et al. Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal block women. J. Glaucoma 8:388-395, 1999.
14. Kitazawa, Y., Azuma, I., Takase, M., et al. Ocular hypotensive effects of carteolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients - a double-masked, crossover study for the determination of concentrations optimal for the clinical use. J. Jpn. Ophthalmol. Soc. 85:798-804, 1981.
15. Sasaki, H., Igarashi, Y., Nagano, T., et al. Penetration of β-blockers through ocular membranes in albino rabbits. J. Pharm. Pharmacol. 47:17-21, 1995.
16. Kato, A., and Iwata, S. In vitro study on corneal permeability to bunazosin. J. Pharmaco. Dyn. 11:115-120, 1988.
17. Lee, V.H.L. Mechanisms and facilitation of corneal drug penetration. J. Contr. Rel. 11:79-90, 1990.
18. Higashiyama, M., Inada, K., Ohtori, A., et al. Improvement of the ocular bioavailability of timolol by sorbic acid. Int. J. Pharm. 272:91-98, 2004.
19. Schoenwald, R.D., and Huang H.S. Corneal penetration behavior of β-blocking agents I: Physicochemical factors. J. Pharm. Sci. 72:1266-1272, 1983.
20. The Merck Index, 12th ed. Whitehouse Station, NJ: MERCK Co., Inc., 1996:8864.
21. Gasco, M.R., Gallarate, M., Trotta, M., et al. Microemulsions as topical delivery vehicles: Ocular administration of timolol. J. Pharm. Biomed. Anal. 7:433-439, 1989.
22. Kato, A., and Iwata, S. Corneal permeability to bunazosin in rabbits. J. Pharmaco. Dyn. 11:181-185, 1988.
23. Gallarate, M., Gasco, M.R., and Trotta, M. Influence of octanoic acid on membrane permeability of timolol from solutions and from microemulsions. Acta. Pharm. Technol. 34:102-105, 1988.
24. Sznitowska, M., Zurowska-Pryczkowska, K., Dabrowska, E., et al. Increased partitioning of pilocarpine to the oily phase of submicron emulsion dose not result in improved ocular bioavailability. Int. J. Pharm. 202:161-164, 2000.
25. Schoenwald, R.D., and Ward R.L. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J. Pharm. Sci. 67:786-788, 1981.
26. Chien, D.S., Bundgaard, H., and Lee, V.H.L. Influence of corneal epithelial integrity on the penetration of timolol prodrugs. J. Ocul. Pharmacol. 4:137-146, 1988.